NASDAQ:NCNA - NuCana Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $16.56 +0.06 (+0.36 %) (As of 12/14/2018 04:00 PM ET)Previous Close$16.56Today's Range$16.5050 - $17.045052-Week Range$9.32 - $32.00Volume10,729 shsAverage Volume37,162 shsMarket Capitalization$524.88 millionP/E Ratio-15.62Dividend YieldN/ABeta7.7 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in preclinical studies for the treatment of solid tumors and hematological malignancies. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom. Receive NCNA News and Ratings via Email Sign-up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NCNA Previous Symbol CUSIPN/A Webwww.nucana.com Phone44-13-1357-1111 Debt Debt-to-Equity RatioN/A Current Ratio16.70 Quick Ratio16.70 Price-To-Earnings Trailing P/E Ratio-15.62 Forward P/E Ratio-27.60 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.78 per share Price / Book4.38 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees20 Outstanding Shares31,810,000Market Cap$524.88 million OptionableNot Optionable NuCana (NASDAQ:NCNA) Frequently Asked Questions What is NuCana's stock symbol? NuCana trades on the NASDAQ under the ticker symbol "NCNA." When is NuCana's next earnings date? NuCana is scheduled to release their next quarterly earnings announcement on Wednesday, March 20th 2019. View Earnings Estimates for NuCana. What price target have analysts set for NCNA? 2 brokerages have issued 1-year target prices for NuCana's stock. Their predictions range from $36.00 to $36.00. On average, they anticipate NuCana's stock price to reach $36.00 in the next year. This suggests a possible upside of 117.4% from the stock's current price. View Analyst Price Targets for NuCana. What is the consensus analysts' recommendation for NuCana? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NuCana. Has NuCana been receiving favorable news coverage? Media stories about NCNA stock have trended somewhat positive on Saturday, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NuCana earned a news sentiment score of 1.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the near future. Who are some of NuCana's key competitors? Some companies that are related to NuCana include Heron Therapeutics (HRTX), Amicus Therapeutics (FOLD), Corcept Therapeutics (CORT), Endocyte (ECYT), Opko Health (OPK), AnaptysBio (ANAB), Pacira Pharmaceuticals (PCRX), Supernus Pharmaceuticals (SUPN), Reata Pharmaceuticals (RETA), Zogenix (ZGNX), Innoviva (INVA), Ironwood Pharmaceuticals (IRWD), Mallinckrodt (MNK), Prestige Consumer Healthcare (PBH) and PTC Therapeutics (PTCT). Who are NuCana's key executives? NuCana's management team includes the folowing people: Mr. Hugh S. Griffith, Founder, CEO & Director (Age 50)Mr. Donald Munoz, Chief Financial Officer (Age 49)Mr. Maxime Laugier, VP of Drug Product When did NuCana IPO? (NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager. Who are NuCana's major shareholders? NuCana's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Capital International Investors (4.53%), Baillie Gifford & Co. (2.60%), Alliancebernstein L.P. (1.71%), Partner Fund Management L.P. (1.22%), Asymmetry Capital Management L.P. (0.27%) and Alps Advisors Inc. (0.18%). Which institutional investors are selling NuCana stock? NCNA stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P.. Which institutional investors are buying NuCana stock? NCNA stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Baillie Gifford & Co., Alliancebernstein L.P., Asymmetry Capital Management L.P., Alps Advisors Inc. and Rothschild Investment Corp IL. How do I buy shares of NuCana? Shares of NCNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is NuCana's stock price today? One share of NCNA stock can currently be purchased for approximately $16.56. How big of a company is NuCana? NuCana has a market capitalization of $524.88 million. The company earns $-29,750,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. NuCana employs 20 workers across the globe. What is NuCana's official website? The official website for NuCana is http://www.nucana.com. How can I contact NuCana? NuCana's mailing address is 3 LOCHSIDE WAY, EDINBURGH X0, EH12 9DT. The company can be reached via phone at 44-13-1357-1111. MarketBeat Community Rating for NuCana (NASDAQ NCNA)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 137 (Vote Outperform)Underperform Votes: 106 (Vote Underperform)Total Votes: 243MarketBeat's community ratings are surveys of what our community members think about NuCana and other stocks. Vote "Outperform" if you believe NCNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NCNA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/15/2018 by MarketBeat.com StaffFeatured Article: What are the economic characteristics of a bear market?